NCT04278781View on ClinicalTrials.gov

AG-120 in People With IDH1 Mutant Chondrosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
ChondrosarcomaChondrosarcoma, Grade 2Chondrosarcoma, Grade 3IDH1 Gene Mutation
Interventions
DRUG

AG-120

AG-120 500 mg orally once daily days 1-28 of a 28-day cycle

Trial Locations (5)

10032

Columbia University (Specimen Analysis Only), New York

10065

Memorial Sloan Kettering Cancer Center, New York

21287

Johns Hopkins Hospital (Data Collection Only), Baltimore

43210

The Ohio State University (Data Collection Only), Columbus

77030

MD Anderson Cancer Center (Data Collection Only), Houston

Sponsors
All Listed Sponsors
collaborator

Agios Pharmaceuticals, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER